['Glucagon-like peptide (GLP)-1-based therapies have been suggested to improve hepatic steatosis. We assessed the effects of the GLP-1 receptor agonist liraglutide and the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin on hepatic steatosis and fibrosis in patients with type 2 diabetes.', 'In this 12\xa0week, parallel, randomised, placebo-controlled trial, performed at the VU University Medical Center between July 2013 and August 2015, 52 overweight patients with type 2 diabetes treated with metformin and/or sulphonylurea agent ([mean ± SD] age 62.7\u2009±\u20096.9\xa0years, HbA', 'One patient dropped out in the sitagliptin group owing to dizziness, but no serious adverse events occurred. At week 12, no between-group differences in hepatic steatosis were found. Liraglutide reduced steatosis by 10% (20.9\u2009±\u20093.4% to 18.8\u2009±\u20093.3%), sitagliptin reduced steatosis by 12.1% (23.9\u2009±\u20093.0% to 21.0\u2009±\u20092.7%) and placebo lessened it by 9.5% (18.7\u2009±\u20092.7% to 16.9\u2009±\u20092.7%). Neither drug affected hepatic fibrosis scores compared with placebo.'] Does twelve week liraglutide or sitagliptin affect hepatic fat in type 2 diabetes : a randomised placebo-controlled trial?